A Study to Evaluate the Effect of Belimumab on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE)

Exclusion Criteria

• •Pregnant or nursing.
• •Have received any prior treatment with belimumab.
• •Have received a live vaccine within the past 30 days.
• •Have received a pneumococcal vaccination with the past 5 years.
• •Have a history of severe allergic reaction to a vaccine, contrast agents (such as those used for x-rays and CT scans), or biological medicines.
• •Have required management of an infection or have had infections that keep coming back within the past 60 days.
• •Hepatitis B: Serologic evidence of Hepatitis B (HB) infection based on the results of testing for HB surface antigen (HBsAg) and anti-HB core antibody (anti-HBc):
• •* Subjects positive for HBsAg are excluded.
• •* Subjects negative for HBsAg but positive for anti-HBc, regardless of anti-HBs antibody status, are excluded.
• •Hepatitis C: Positive test for Hepatitis C antibody.
• •Known human immunodeficiency virus (HIV) infection.
• •Have current drug or alcohol abuse or dependence.
• •Have a Grade 3/4 immunoglobulin (Ig)G deficiency (IgG level \<400 milligrams \[mg\]/ deciliter \[dL\]) or IgA deficiency (IgA level \<10 mg/dL).
• •Subjects who have evidence of serious suicide risk including any history of suicidal behavior in the last 6 months and/or suicidal ideation with some intent to act in the last 2 months or who in the investigator's judgment, pose a significant suicide risk.